Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    87,375.28
    +1,190.12 (+1.38%)
     

  • CMC Crypto 200

    1,326.94
    +49.97 (+3.91%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Zacks Equity Research
Updated
Is (LXFR) Outperforming Other Industrial Products Stocks This Year?

Investors focused on the Medical space have likely heard of Gilead Sciences (GILD), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GILD and the rest of the Medical group's stocks.

Gilead Sciences is a member of the Medical sector. This group includes 758 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 14.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

ADVERTISEMENT

Based on the most recent data, GILD has returned 5.51% so far this year. Meanwhile, the Medical sector has returned an average of 5.14% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.

To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, this group has lost an average of 2.42% so far this year, meaning that GILD is performing better in terms of year-to-date returns.

GILD will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.